Clinical Trial Update: Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluates the immunogenicity and safety of a 9-valent human papillomavirus vaccine in HIV-positive women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection
• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: University Hospital Virgen de las Nieves | Conditions: HIV Infections, HPV Infection | Phase 4 | Status: ACTIVE_NOT_RECRUITING